Executive Reshuffles: Otis Worldwide, HSBC and Rockwell Automation in Focus
BeiGene Appoints CFO
BeiGene (HKG:6160) appointed Aaron Rosenberg as its chief financial officer effective from July 22, a Thursday filing with the Hong Kong Exchange said.Aaron will succeed Julia Wang who has resigned
BeiGene Names Rosenberg Finance Chief as Wang Departs
By Colin Kellaher Oncology company BeiGene is replacing its top finance executive. BeiGene on Thursday said Aaron Rosenberg is joining the company as chief financial officer effective July 22, while
Beigene (06160.HK) has appointed Aaron Rosenberg as its Chief Financial Officer.
Beigene (06160.HK) announced on July 18 that Aaron Rosenberg has been appointed Chief Financial Officer of the company, effective from July 22, 2024. Mr. Rosenberg will succeed Julia Wang, who will leave to seek external opportunities. Ms. Wang will continue to serve until the end of August to help with the transition.
BeiGene Announces New CFO Appointment and Senior Advisor Transition
Express News | Beigene - Aaron Rosenberg Has Been Appointed as Chief Financial Officer
Express News | Beigene Has Appointed Aaron Rosenberg As Chief Financial Officer, Effective July 22 Succeeding Julia Wang, Who Is Departing To Pursue External Opportunities And Will Stay With The Company Through August To Support The Transition
Express News | Beigene - Rosenberg Will Succeed Julia Wang
Express News | Beigene Announces Appointment of Aaron Rosenberg as Chief Financial Officer
BeiGene: Julia Wang Is Departing to Pursue External Opportunities >BGNE
BeiGene: Julia Wang Is Departing to Pursue External Opportunities >
BeiGene Announces Appointment Of Aaron Rosenberg As Chief Financial Officer >BGNE
BeiGene Announces Appointment Of Aaron Rosenberg As Chief Financial Officer >
Nomura Adjusts BeiGene's Price Target to HK$158.37 From HK$150, Keeps at Buy
03:24 AM EDT, 07/16/2024 (MT Newswires) -- Nomura Adjusts BeiGene's Price Target to HK$158.37 From HK$150, Keeps at BuyPrice (HKD): $90.20, Change: $+0.40, Percent Change: +0.45%
Nomura: Maintains Buy Rating for Beigene, Target Price Increased to HKD 158.37.
Nomura released a research report stating that it maintains a "buy" rating for Beigene (06160), with a target price raised from HKD 150 to HKD 158.37. The company is expected to achieve sales of $ 0.833 billion in the second quarter of the 2024 fiscal year, a 40% increase YoY and an 11% increase QoQ, which is 4% higher than market expectations. The bank stated that it has raised its revenue forecast for the company for fiscal years 2024 and 2025 by 14% each to $ 3.1 billion and $ 4 billion respectively. This is mainly due to the upward revision of the two-year sales forecast for Zanubrutinib, from the original $ 1.6 billion and $ 2 billion each to $ 2 billion and $ 2.5 billion each.
Nomura: Maintains a "buy" rating for Beigene (06160) with a target price of HKD 158.37.
Zhixin Finance App learned that Nomura released a research report stating that it maintains a "buy" rating on Beigene (06160) and raised its target price from HKD 150 to HKD 158.37. It is expected that the company's sales in the second quarter of fiscal year 2024 will reach USD 0.833 billion, a year-on-year increase of 40%, and a quarterly increase of 11%, which is 4% higher than the market expectation. The bank stated that it raised its revenue forecast for the company's fiscal year 2024 and 2025 by 14% each to USD 3.1 billion and USD 4 billion, mainly due to the increase in sales forecast of Zanubrutinib for two years, raised from the original USD 1.6 billion and USD 2 billion to USD 2 billion each.
Express News | BeiGene Shares Are Trading Lower After B of A Securities Maintained a Neutral Rating on the Stock and Lowered Its Price Target From $180 to $152.5
Asian Equities Traded in the US as American Depositary Receipts Rise Sharply in Friday Trading
Asian equities traded in the US as American depositary receipts were moving sharply higher Friday morning, rising 1.2% to 2,061.9 on the S&P Asia 50 ADR Index. With the gain, the index is poised to
BeiGene (NASDAQ:BGNE) Shareholders Have Endured a 55% Loss From Investing in the Stock Three Years Ago
The truth is that if you invest for long enough, you're going to end up with some losing stocks. Long term BeiGene, Ltd. (NASDAQ:BGNE) shareholders know that all too well, since the share price is
When Will BeiGene, Ltd. (NASDAQ:BGNE) Become Profitable?
BeiGene Price Target Cut to $152.50/Share From $180.00 by B of A Securities
BeiGene Price Target Cut to $152.50/Share From $180.00 by B of A
BeiGene Is Maintained at Neutral by B of A Securities
BeiGene Is Maintained at Neutral by B of A